Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 8/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30385056 | 1.00 | EGFR (0.39) | EGFRERBB2ALKMAPTLMNA | |
| SCHEMBL17670222 | 0.94 | EGFR (0.46) | EGFRERBB2MAPTLMNAALDH1A1 | |
| SCHEMBL30385164 | 0.89 | EGFR (0.40) | EGFRERBB2ALKMAPTLMNA | |
| SCHEMBL17670194 | 0.89 | EGFR (0.40) | EGFRERBB2ALKMAPTLMNA | |
| SCHEMBL17670196 | 0.88 | EGFR (0.39) | EGFRERBB2ALKMAPTLMNA | |
| SCHEMBL30384985 | 0.88 | EGFR (0.39) | EGFRERBB2ALKMAPTLMNA | |
| SCHEMBL17670169 | 0.88 | EGFR (0.39) | EGFRERBB2ALKMAPTLMNA | |
| SCHEMBL30384575 | 0.88 | EGFR (0.39) | EGFRERBB2ALKMAPTLMNA | |
| SCHEMBL17670292 | 0.87 | EGFR (0.36) | EGFRERBB2ALKMAPTLMNA | |
| SCHEMBL17670205 | 0.87 | EGFR (0.49) | EGFRERBB2ALKMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725554-A2 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | Yuhan Corporation (KR) | 2026-04-15 | — | — | EP | disclosed |
| US-RE50528-E1 | Compounds and compositions for modulating EGFR mutant kinase activities | YUHAN CORPORATION (KR) | 2025-08-12 | — | — | US | disclosed |
| EP-3929190-B1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | YUHAN CORP (KR) | 2024-12-25 | — | — | EP | disclosed |
| EP-4421069-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | Yuhan Corporation (KR) | 2024-08-28 | — | — | EP | disclosed |
| CN-111686110-B | Compounds and compositions for modulating EGFR mutant kinase activity | 株式会社柳韩洋行 | 2023-06-16 | — | — | CN | disclosed |
| EP-3604294-B1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | YUHAN CORP (KR) | 2021-05-05 | — | — | EP | disclosed |
| CN-111686110-A | Compounds and compositions for modulating EGFR mutant kinase activity | 株式会社柳韩洋行 | 2020-09-22 | — | — | CN | disclosed |
| CN-106795144-B | Compounds and compositions for modulating EGFR mutant kinase activity | 株式会社柳韩洋行 | 2020-06-16 | — | — | CN | disclosed |
| EP-3604294-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | Yuhan Corporation (KR) | 2020-02-05 | — | — | EP | disclosed |
| EP-3207035-B1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | YUHAN CORP (KR) | 2019-11-20 | — | — | EP | disclosed |
| US-9593098-B2 | Compounds and compositions for modulating EGFR mutant kinase activities | YUHAN CORPORATION (KR) | 2017-03-14 | — | — | US | disclosed |
| US-20160102076-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | YUHAN CORPORATION | 2016-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102076-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | EGFR, ERBB2, ERBB3 | EGFR 1/4885ERBB2 2/4885ALK 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.